Literature DB >> 30616916

Polycystic ovary syndrome in adult women.

Andrés E Ortiz-Flores1, Manuel Luque-Ramírez1, Héctor F Escobar-Morreale2.   

Abstract

Polycystic ovary syndrome is the most prevalent endocrine-metabolic pathology in pre-menopausal women. Its etiopathogenesis is complex, multifactorial and heterogeneous, including the interaction of genetic, epigenetic and environmental factors. Androgenic excess constitutes the disease's main physiopathological mechanism and results in reproductive, metabolic and cosmetic alterations which negatively impact these patients' quality of life. The criteria established in the Rotterdam consensus and their correct application form the necessary basis for this syndrome's proper diagnosis. In the absence of an aetiological treatment, the aim is to improve the clinical signs and symptoms derived from hyperandrogenism, ovarian dysfunction and existing metabolic complications, and, therefore, they must be chronic and individualised.
Copyright © 2018 Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Disfunción ovulatoria; Hiperandrogenismo; Hyperandrogenism; Obesidad; Obesity; Ovulatory dysfunction; Subfertilidad; Subfertility

Year:  2019        PMID: 30616916     DOI: 10.1016/j.medcli.2018.11.019

Source DB:  PubMed          Journal:  Med Clin (Barc)        ISSN: 0025-7753            Impact factor:   1.725


  9 in total

1.  Integrated Network Pharmacology and Clinical Study to Reveal the Effects and Mechanisms of Bushen Huoxue Huatan Decoction on Polycystic Ovary Syndrome.

Authors:  Jie Ding; Mei Shanshan; Cai Mengcheng; Zhang Danying; Yu Jin
Journal:  Evid Based Complement Alternat Med       Date:  2022-05-13       Impact factor: 2.650

Review 2.  Endocrine disruptors of sex hormone activities.

Authors:  L Varticovski; D A Stavreva; A McGowan; R Raziuddin; G L Hager
Journal:  Mol Cell Endocrinol       Date:  2021-07-30       Impact factor: 4.102

3.  The relationship between polycystic ovary syndrome and infertility: a bibliometric analysis.

Authors:  Sulian Zhuang; Chunxia Jing; Lei Yu; Liwei Ji; Weiwei Liu; Xingpo Hu
Journal:  Ann Transl Med       Date:  2022-03

Review 4.  Blood pressure in postmenopausal women with a history of polycystic ovary syndrome.

Authors:  Katarzyna Doroszewska; Tomasz Milewicz; Sandra Mrozińska; Jarosław Janeczko; Radosław Rokicki; Marek Janeczko; Damian Warzecha; Piotr Marianowski
Journal:  Prz Menopauzalny       Date:  2019-06-14

5.  The risk factors of gestational hypertension in patients with polycystic ovary syndrome: a retrospective analysis.

Authors:  Shu Zhou; Yiping Ji; Haimei Wang
Journal:  BMC Pregnancy Childbirth       Date:  2021-04-27       Impact factor: 3.007

6.  The Effects of Letrozole and Metformin Combined with Targeted Nursing Care on Ovarian Function, LH, and FSH in Infertile Patients with Polycystic Ovary Syndrome.

Authors:  Shuai Jiang; Ting Tang; Yongmei Sheng; Rui Li; Hua Xu
Journal:  J Healthc Eng       Date:  2022-03-23       Impact factor: 2.682

Review 7.  Diabetes, Polycystic Ovarian Syndrome, Obstructive Sleep Apnea, and Obesity: A Systematic Review and Important Emerging Themes.

Authors:  Zarna Bambhroliya; Joel Sandrugu; Michael Lowe; Oluwasemilore Okunlola; Shafaat Raza; Stephen Osasan; Sudiksha Sethia; Tayyaba Batool; Pousette Hamid
Journal:  Cureus       Date:  2022-06-25

Review 8.  Polycystic Ovary Syndrome in Insulin-Resistant Adolescents with Obesity: The Role of Nutrition Therapy and Food Supplements as a Strategy to Protect Fertility.

Authors:  Valeria Calcaterra; Elvira Verduci; Hellas Cena; Vittoria Carlotta Magenes; Carolina Federica Todisco; Elisavietta Tenuta; Cristina Gregorio; Rachele De Giuseppe; Alessandra Bosetti; Elisabetta Di Profio; Gianvincenzo Zuccotti
Journal:  Nutrients       Date:  2021-05-28       Impact factor: 5.717

9.  Elevated Anti-Müllerian Hormone Levels in Newborns of Women with Polycystic Ovary Syndrome: a Systematic Review and Meta-analysis Based on Observational Studies.

Authors:  Siyu Zhou; Danhua Lu; Shu Wen; Yongcheng Sheng; Deying Kang; Liangzhi Xu
Journal:  Reprod Sci       Date:  2021-06-15       Impact factor: 3.060

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.